Impact Factor
4.67
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
11.21
2,531 total citations
h5-index
69
h5 depth signal
Cited share
89.1%
213 of 239
Total citations
2,531
Citation footprint
Metric signal
12.00
External metric anchor
Self-citation
0.6%
16 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Italy
404
United States
324
United Kingdom
185
France
180
Spain
171
Citing Fields of Research
Oncology
480
Breast Cancer
263
Immunology
238
Lung Cancer
151
Liver & Colon Cancer
123
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
4,039
Articles tracked across the journal lifetime
Indexed publication set
239
213 cited publications
Last 12 months
123
10.3 publications/month
Open access share
45.5%
56 OA publications in the last year
Leading citing country
Italy
404 citing publications
Leading citing field
Oncology
480 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v1n1,Mar. 1974-
v1n1,Mar. 1974-
Active Coverage
Research Focus & Classification
Indexed Subjects
Breast Cancer
Oncology
Immunology
Lung Cancer
Broad Categories
Antineoplastic Agents
Neoplasms
Immunology
Lung Cancer
Breast Cancer
Liver & Colon Cancer
Musculoskeletal & Nerve Cancer
Prostate Cancer
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/j.ctrv.2026.103235
Open DOI
Role of maintaining the TKI backbone in oncogene-driven NSCLC after progression
02
03
DOI 10.1016/s0305-7372(26)00144-1
Open DOI
Editorial Board
04
DOI 10.1016/j.ctrv.2026.103222
Open DOI
Exercise as anticancer medicine? Evidence, mechanisms and implementation in oncology
05
DOI 10.1016/j.ctrv.2026.103225
Open DOI
CDH1 germline carriers and diffuse gastric Cancer: Are we ready for personalized surveillance and prevention?
06
DOI 10.1016/j.ctrv.2026.103224
Open DOI
Targeted protein degradation as next-generation therapeutic modality for childhood cancer
07
DOI 10.1016/j.ctrv.2026.103223
Open DOI
Artificial intelligence–enabled drug discovery: A growing but largely early-stage clinical pipeline
08
DOI 10.1016/j.ctrv.2026.103221
Open DOI
Molecular tumor boards implementation in Europe: a scoping review and thematic analysis of challenges and facilitators
09
DOI 10.1016/j.ctrv.2026.103219
Open DOI
The prognostic value of pathological response in soft tissue sarcoma: A systematic review
10
DOI 10.1016/j.ctrv.2026.103218
Open DOI
Advancing therapies for HER2-positive metastatic breast cancer: Navigating a wealth of treatment options
Bibliographical & Catalog Notes
Editors: 1974- K. Hellmann and S. K. Carter.
Also issued online.
Vol. 17, no. 1 (1990)19901002 Notice published Printed on acid-free paper